BAT Vuse Go 800 Dominates Korean E-cigarette Market

BAT by 2FIRSTS.ai
Jan.19.2024
BAT Vuse Go 800 Dominates Korean E-cigarette Market
BAT's e-cigarette "Vuse Go 800" is rapidly dominating the market in South Korea, expanding its sales network to 30,000 stores.

According to a report from the Korean Culture Daily on January 18th, the e-liquide-cigarette "Vuse Go 800" launched by British American Tobacco (BAT) is rapidly gaining market share in the e-cigarette industry in South Korea. Its sales network is continuously expanding and has now reached Seoul, as well as over 30,000 convenience stores and e-cigarette shops.

 

This closed-system e-cigarette was first launched in South Korea in July of last year and further expanded its product line in September by introducing four new flavors, including "Purple Breeze," "Green Spark," "Ice Fresh," and "Summer Fresh," specifically for the Seoul region.

 

British American Tobacco has announced its intention to establish a leading e-cigarette brand in South Korea, with the "Vuse Go 800" as its flagship product. The company emphasized its commitment to strengthening its non-combustible product portfolio and offering more diverse options to the mature smoking population in South Korea.

 

A spokesperson for a British-American tobacco company stated, "Despite its limited release in certain regions, the sales of 'Vuse Go 800' have exceeded our initial expectations." He further disclosed that the company is rapidly responding to meet consumer demands and has plans to diversify its product line.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
Feb.11
Haypp confirms exit from UK vape category as it shifts focus to oral nicotine
Haypp confirms exit from UK vape category as it shifts focus to oral nicotine
Haypp, an online retailer of alternative nicotine products, has confirmed it is exiting the UK vape category as it shifts focus to the oral nicotine market. The company said analysis of its sales data showed increasing adoption of nicotine pouches across its six international markets: the UK, the USA, Germany, Norway, Switzerland and Sweden.
Mar.04 by 2FIRSTS.ai
Milton Police Call It Florida’s Largest Illegal Vape Seizure, With 500+ Products Confiscated Across Seven Stores
Milton Police Call It Florida’s Largest Illegal Vape Seizure, With 500+ Products Confiscated Across Seven Stores
According to a Milton Police Department (MPD) news release, Milton, Florida officers and partner agencies carried out compliance checks at seven vape retailers on Jan. 27, seizing more than 500 illegal vape products and arresting employees allegedly involved in sales to minors. Authorities also reported finding unlicensed marijuana sales, high-THC products, nitrous oxide and illegal charging units.
Jan.29 by 2FIRSTS.ai
Fourth Circuit denies rehearing bid over stay allowing Virginia e-cigarette rules to be enforced
Fourth Circuit denies rehearing bid over stay allowing Virginia e-cigarette rules to be enforced
The U.S. Court of Appeals for the Fourth Circuit has declined to grant en banc or other rehearing of its decision to stay an order that had blocked enforcement of certain Virginia e-cigarette regulations. In a brief order filed Tuesday, the court denied a rehearing petition by Nova Distro Inc. and Tobacco Hut and Vape Fairfax Inc., noting that no judge requested a poll on the petition.
Mar.05 by 2FIRSTS.ai
IQOS Japan launches three ILUMA i custom bundle sets with leather wrap and premium ring accessories, on sale from Jan 29
IQOS Japan launches three ILUMA i custom bundle sets with leather wrap and premium ring accessories, on sale from Jan 29
According to IQOS Japan’s official website, the company has introduced three custom bundle sets for its IQOS ILUMA i lineup, combining devices with accessories as bundled offerings, and began rolling them out across multiple sales channels from Jan. 29.
Jan.29 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24